These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16155817)

  • 21. Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis.
    Falck RS; Wang J; Carlson RG
    J Psychopharmacol; 2008 Jan; 22(1):47-54. PubMed ID: 18187532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence.
    Meyer JS; Piper BJ; Vancollie VE
    Ann N Y Acad Sci; 2008 Oct; 1139():151-63. PubMed ID: 18991859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of ecstasy on the body].
    Saarijärvi S; Lopperi M
    Duodecim; 2003; 119(13):1211-5. PubMed ID: 12908183
    [No Abstract]   [Full Text] [Related]  

  • 24. Epidemiology of MDMA and associated club drugs in the Seattle area.
    Banta-Green C; Goldbaum G; Kingston S; Golden M; Harruff R; Logan BK
    Subst Use Misuse; 2005; 40(9-10):1295-315. PubMed ID: 16048818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Club drug use in Germany.
    Soellner R
    Subst Use Misuse; 2005; 40(9-10):1279-93. PubMed ID: 16048817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuropsychiatric disorders induced by MDMA ("Ecstasy")].
    Bailly D
    Encephale; 1999; 25(6):595-602. PubMed ID: 10668603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Uys JD; Niesink RJ
    Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Psychological aspects of MDMA (ecstasy) users].
    Varescon I
    Ann Med Interne (Paris); 2003 Nov; 154 Spec No 2():S81-5. PubMed ID: 14760230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.
    Reneman L; de Win MM; van den Brink W; Booij J; den Heeten GJ
    J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The neuropsychology of ecstasy (MDMA) use: a quantitative review.
    Zakzanis KK; Campbell Z; Jovanovski D
    Hum Psychopharmacol; 2007 Oct; 22(7):427-35. PubMed ID: 17896346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.
    McCann UD; Ricaurte GA
    J Clin Psychopharmacol; 1991 Oct; 11(5):302-5. PubMed ID: 1684975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
    Medina KL; Shear PK; Corcoran K
    J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recreational ecstasy use and the neurotoxic potential of MDMA: current status of the controversy and methodological issues.
    Lyvers M
    Drug Alcohol Rev; 2006 May; 25(3):269-76. PubMed ID: 16753651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction.
    Quednow BB; Jessen F; Kuhn KU; Maier W; Daum I; Wagner M
    J Psychopharmacol; 2006 May; 20(3):373-84. PubMed ID: 16574711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
    Camarasa J; Pubill D; Escubedo E
    Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ecstasy toxicity].
    Reingardiene D
    Medicina (Kaunas); 2006; 42(6):519-23. PubMed ID: 16816548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls.
    Lamers CT; Bechara A; Rizzo M; Ramaekers JG
    J Psychopharmacol; 2006 Mar; 20(2):302-11. PubMed ID: 16510488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.
    Daumann J; Till B; Fischermann T; Rezk M; Gouzoulis-Mayfrank E
    J Psychopharmacol; 2006 Mar; 20(2):236-44. PubMed ID: 16510481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
    Thomasius R; Schmolke M; Kraus D
    Fortschr Neurol Psychiatr; 1997 Feb; 65(2):49-61. PubMed ID: 9157047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.